Latest News for: nmda

Edit

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy

ACCESSWIRE 17 Jun 2026
Food and Drug Administration (FDA) for Ketamir-2, the Company's proprietary oral NMDA receptor modulator, in chemotherapy-induced peripheral neuropathy (CIPN) ... Ketamir-2 is an oral NMDA receptor modulator in development for chronic neuropathic pain.
Edit

MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets ...

ACCESSWIRE 27 May 2026
Ketamir-2 is MIRA's proprietary oral NMDA receptor modulator currently advancing toward planned Phase 2a development in chemotherapy-induced peripheral neuropathy ("CIPN"), an indication with significant unmet medical need.
Edit

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2

ACCESSWIRE 14 May 2026
Selective oral NMDA receptor modulator demonstrated favorable safety, tolerability, and pharmacokinetic profile supporting planned Phase 2a development in chemotherapy-induced peripheral neuropathy.
  • 1

Article Search

tools
×
×
×
×